The US saw fewer drug shortages in 2025, but surging product discontinuations and a supply chain tethered to China and India for key starting materials and also the EU for APIs highlight vulnerabilities, especially amid geopolitical turbulence.
The US saw fewer drug shortages in 2025, but surging product discontinuations and a supply chain tethered to China and India for key starting materials and also the EU for APIs highlight vulnerabilities, especially amid geopolitical turbulence.